title: [Preference for etanercept pen versus syringe in patients with chronic arthritis. Nurse education workshop].
abstract: OBJECTIVE
  The aims of this study are to evaluate the level of fear of post-injection pain prior to the administration, the difficulty in handling the device, and the level of satisfaction of patients using a pre-filled syringe versus an etanercept pen, as well as to evaluate the usefulness of the training given by nursing staff prior to starting with the pen, and the preferences of patients after using both devices.
  
  
  METHODS
  A prospective study was designed to follow-up a cohort of patients during a 6 months period. The data was collected using questionnaires and analyzed with SPSS 18.00. Rank and McNemar tests were performed. Statistical significance was pre-set at an α level of 0.05.
  
  
  RESULTS
  A total of 29 patients were included, of whom 69% female, and with a mean age 52.5±10.9 years. Of these, 48% had rheumatoid arthritis, 28% psoriatic arthritis, 21% ankylosing spondylitis, and 3% undifferentiated spondyloarthropathy. There were no statistically significant differences either with the fear or pain or handling of the device between the syringe and the pen (P=.469; P=.812; P=.169 respectively). At 6 months, 59% of patients referred to being satisfied or very satisfied with the pen. Almost all (93%) found useful or very useful the training given by nursing staff prior to using the pen, and 55% preferred the pen over the pre-filled syringe.
  
  
  CONCLUSIONS
  The etanercept pen is another subcutaneous device option for patients with chronic arthritis. According to the present study, nursing educational workshops before starting this therapy are recommended.
authors.affiliation: Servicio de Reumatología, Hospital Moisès Broggi Sant Joan Despí, Consorci Sanitari Integral CSI, Barcelona, España. sgdphy@yahoo.es
authors.forename: Silvia
authors.initials: S
authors.lastname: Garcia-Diaz
authors.forename: Montserrat
authors.initials: M
authors.lastname: Girabent-Farrés
authors.forename: Daniel
authors.initials: D
authors.lastname: Roig-Vilaseca
authors.forename: Delia
authors.initials: D
authors.lastname: Reina
authors.forename: Dacia
authors.initials: D
authors.lastname: Cerdà
authors.forename: Marina
authors.initials: M
authors.lastname: González
authors.forename: Vicenç
authors.initials: V
authors.lastname: Torrente-Segarra
authors.forename: Ramon
authors.initials: R
authors.lastname: Fíguls
authors.forename: Hèctor
authors.initials: H
authors.lastname: Corominas
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D001168:Arthritis / Q000188:drug therapy*; D002908:Chronic Disease; D004506:Education, Nursing; D004867:Equipment Design; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D057240:Patient Preference; D011446:Prospective Studies; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage*; D013594:Syringes
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept
keywords: Ankylosing spondylitis; Artritis psoriásica; Artritis reumatoide; Autoadministración; Espondilitis anquilosante; Etanercept; Inyección subcutánea; Psoriatic arthritis; Rheumatoid arthritis; Self-administration; Subcutaneous injection